Survivals following discontinuation of PD-1 inhibitor treatment in advanced melanoma patients.
Journal
Melanoma research
ISSN: 1473-5636
Titre abrégé: Melanoma Res
Pays: England
ID NLM: 9109623
Informations de publication
Date de publication:
01 02 2023
01 02 2023
Historique:
pubmed:
17
11
2022
medline:
24
12
2022
entrez:
16
11
2022
Statut:
ppublish
Résumé
The aim of this study was to evaluate overall survival post-treatment discontinuation survival (OS PTD ) in advanced melanoma patients started on immunotherapy. This retrospective study included all unresectable advanced or metastatic melanoma patients who had permanent treatment discontinuation after receiving at least one cycle of palliative-intent programmed death-1 ± cytotoxic T-lymphocyte associated protein-4 inhibitor treatment from 2014 to 2019. Indications of permanent treatment discontinuation included treatment completion, toxicity or progression. OS PTD was defined as a time of permanent treatment discontinuation to the time of death. Our study ( N = 96) had 27, 12 and 57 patients who discontinued PD-1 inhibitor treatment due to treatment completion, toxicity and progression, respectively. Median treatment durations received for the treatment completion, toxicity and progression groups were 24, 6 and 3 months, respectively. As expected those patients who had disease progression on immunotherapy had very poor survival compared to those that completed treatment or stopped due to toxicity. A multivariable Cox model excluding the patients who progressed indicated no significant OS PTD differences between the toxicity and treatment completion group (HR, 0.894; 95% CI, 0.232-3.449; P = 0.871) who received single or dual immunotherapy. Our real-world study highlighted similar, durable survival at PD-1 inhibitor discontinuation due to either toxicity or treatment completion, despite longer treatment duration received in the completion group than toxicity group. Patients with progression on PD-1 inhibitor treatment have very poor survival. Our findings must be interpreted with caution due to its retrospective nature and small sample size.
Identifiants
pubmed: 36382411
doi: 10.1097/CMR.0000000000000858
pii: 00008390-202302000-00005
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
50-57Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019; 381:1535–1546.
Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 2019; 20:1239–1251.
Hodi FS, Chiarion-Sileni V, Lewis KD, et al. Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in Checkmate-067. J Clin Oncol 2022; 40(suppl_16):9522–9522.
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 2019; 30:582–588.
Dimitriou F, Zaremba A, Allayous C, Kähler KC, Gerard CL, Festino L, et al. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. Eur J Cancer 2021; 149:37–48.
Asher N, Israeli-Weller N, Shapira-Frommer R, Ben-Betzalel G, Schachter J, Meirson T, Markel G. Immunotherapy discontinuation in metastatic melanoma: lessons from real-life clinical experience. Cancers (Basel) 2021; 13:3074.
Valentin J, Ferté T, Dorizy-Vuong V, Dousset L, Prey S, Dutriaux C, et al. Real-world survival in patients with metastatic melanoma after discontinuation of anti-PD-1 immunotherapy for objective response or adverse effects: a retrospective study. J Oncol 2021;2021:5524685.
de Ávila Machado MA, de Moura CS, Chan K, et al. Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients. Sci Rep 2020; 10:14607.
Regan MM, Mantia CM, Werner L, Tarhini AA, Larkin J, Stephen Hodi F, et al. Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067. J Immunother Cancer 2021; 9:e003743.
Regan MM, Werner L, Rao S, Gupte-Singh K, Hodi FS, Kirkwood JM, et al. Treatment-free survival: a novel outcome measure of the effects of immune checkpoint inhibition-a pooled analysis of patients with advanced melanoma. J Clin Oncol 2019; 37:3350–3358.
Mazzola R, Jereczek-Fossa BA, Franceschini D, Tubin S, Filippi AR, Tolia M, et al. Oligometastasis and local ablation in the era of systemic targeted and immunotherapy. Radiat Oncol 2020; 15:92.
Youland RS, Blanchard ML, Dronca R, Kottschade L, Markovic SN, Olivier KR, Park SS. Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era. Clin Transl Radiat Oncol 2017; 6:25–30.
Grossman CE, Okunieff P, BRasacchio RA, et al. Stereotatic body radiation therapy for oligometastatic renal cell carcinoma or melanoma: prognostic factors and outcomes. Int J of Rad Oncol*Biol*Physics 2015; 9(supp_1):E202.
Fundytus A, Prasad V, Booth CM. Has the current oncology value paradigm forgotten patients’ time?: too little of a good thing. JAMA Oncol 2021;7:1757–1758.
Gupta A, Jensen EH, Virnig BA, Beg MS. Time-related burdens of cancer care. JCO Oncol Pract 2022;18:245–246.
Oh A, Tran DM, McDowell LC, Keyvani D, Barcelon JA, Merino O, Wilson L. Cost-effectiveness of nivolumab-ipilimumab combination therapy compared with monotherapy for first-line treatment of metastatic melanoma in the United States. J Manag Care Spec Pharm 2017; 23:653–664.
Andrews A. Treating with checkpoint inhibitors-figure $1 million per patient. Am Health Drug Benefits 2015; 8:9.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Melanoma: Cutaneous. Version 1.2022, December 3, 2021. Retrieved on December 15 2021 from: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
Holstead RG, Kartolo BA, Hopman WM, Baetz TD. Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors. Melanoma Res 2021; 31:258–263.
Suo A, Chan Y, Beaulieu C, Kong S, Cheung WY, Monzon JG, et al. Anti-PD1-induced immune-related adverse events and survival outcomes in advanced melanoma. Oncologist 2020; 25:438–446.
Nakamura Y, Tanaka R, Asami Y, Teramoto Y, Imamura T, Sato S, et al. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study. J Dermatol 2017; 44:117–122.
Petrelli F, Signorelli D, Ghidini M, Ghidini A, Pizzutilo EG, Ruggieri L, et al. Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers (Basel) 2020; 12:E546.
Zhao Q, Zhang J, Xu L, Yang H, Liang N, Zhang L, et al. Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: a systemic review and meta-analysis. Front Immunol 2021; 12:730320.
Kartolo A, Holstead R, Khalid S, Emack J, Hopman W, Baetz T. Safety of immunotherapy rechallenge after immune-related adverse events in patients with advanced cancer. J Immunother 2021; 44:41–48.
Allouchery M, Lombard T, Martin M, et al. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade≥2 immune-related adverse events in patients with cancer. J for Immunother of Cancer 2020; 8:e001622.